Adiponectin in a Native Canadian Population Experiencing Rapid Epidemiological Transition

  1. Anthony J.G. Hanley, PHD123,
  2. Philip W. Connelly, PHD245,
  3. Stewart B. Harris, MD6 and
  4. Bernard Zinman, MD12
  1. 1Leadership Sinai Centre for Diabetes, Mt. Sinai Hospital, Toronto, Ontario, Canada
  2. 2Department of Medicine, University of Toronto, Toronto, Ontario, Canada
  3. 3Department of Public Health Sciences, University of Toronto, Toronto, Ontario, Canada
  4. 4Department of Laboratory Medicine and Pathobiology, University of Toronto, Toronto, Ontario, Canada
  5. 5J. Alick Little Lipid Research Laboratory, St. Michael’s Hospital, Toronto, Ontario, Canada
  6. 6Centre for Studies in Family Medicine, University of Western Ontario, London, Ontario, Canada
  1. Address correspondence and reprint requests to Anthony Hanley, PhD, Leadership Sinai Centre for Diabetes, Mt. Sinai Hospital, 60 Murray St., Room 5210, Toronto, Ontario, M5G 1X5 Canada. E-mail: hanley{at}mshri.on.ca

Abstract

OBJECTIVE—Adiponectin is emerging as an important protein in the etiology of obesity and related metabolic disorders. The objectives of this study were to determine cross-sectional and prospective associations of adiponectin concentration with adiposity, type 2 diabetes, and cardiovascular disease (CVD) risk factors in a population-based study of Native Canadians, a group experiencing dramatic increases in diabetes and CVD.

RESEARCH DESIGN AND METHODS—During the 1993–1995 baseline survey, samples for glucose, insulin, adiponectin, and lipids were collected after an overnight fast. Waist circumference and percent body fat were measured, and a 75-g oral glucose tolerance test was administered: n = 505 with normal glucose tolerance (NGT), 74 with impaired glucose tolerance (IGT), and 149 with diabetes. In 1998, 95 high-risk subjects, defined as those who, at baseline, had either IGT or NGT with an elevated 2-h glucose concentration (≥7.0 mmol/l), participated in a follow-up examination using the protocol used at baseline.

RESULTS—After adjustment for covariates including percent body fat and homeostasis model assessment of insulin resistance (HOMA-IR), adiponectin concentrations were significantly lower among men versus women (10.8 vs. 15.0 μg/ml, P < 0.0001) and among diabetic versus NGT subjects (11.1 vs. 13.1 μg/ml, P < 0.05). Adiponectin was inversely correlated with percent body fat, waist circumference, HOMA-IR, and triglyceride and positively correlated with HDL (r = |0.30|–|0.44|, all P < 0.0001). In multivariate linear regression analysis in nondiabetic subjects, HDL and percent body fat were significantly related to adiponectin variation among both men and women (R2 = 28–29%). Factor analysis returned three underlying factors among these variables, with adiponectin loading on the second factor along with insulin, waist circumference, triglyceride, and HDL. In the follow-up study, higher adiponectin at baseline was significantly associated with increases in HDL (r = 0.24, P = 0.03) and decreases in HOMA-IR (r = −0.29, P = 0.009) after adjustment for covariates, including age, adiposity, and diabetes status at baseline and follow-up.

CONCLUSIONS—These population-based findings support the hypothesis that low circulating levels of adiponectin are an important determinant of risk of CVD.

Footnotes

  • A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

    • Accepted August 26, 2003.
    • Received July 11, 2003.
« Previous | Next Article »Table of Contents